Serial changes of international prostate symptom score following I-125 prostate brachytherapy

Toshio Ohashi, Atsunori Yorozu, Kazuhito Toya, Shiro Saito, Tetsuo Momma

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8%) and it returned to within 3 points of the baseline in 64 (62.1%) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.

Original languageEnglish
Pages (from-to)320-325
Number of pages6
JournalInternational Journal of Clinical Oncology
Volume11
Issue number4
DOIs
Publication statusPublished - 2006 Aug
Externally publishedYes

Fingerprint

Brachytherapy
Prostate
Group Psychotherapy
Iodine
Prostatic Neoplasms
Radiotherapy
Therapeutics
Multivariate Analysis

Keywords

  • Brachytherapy
  • Iodine-125
  • IPSS
  • Prostate cancer
  • Urinary morbidity

ASJC Scopus subject areas

  • Oncology

Cite this

Serial changes of international prostate symptom score following I-125 prostate brachytherapy. / Ohashi, Toshio; Yorozu, Atsunori; Toya, Kazuhito; Saito, Shiro; Momma, Tetsuo.

In: International Journal of Clinical Oncology, Vol. 11, No. 4, 08.2006, p. 320-325.

Research output: Contribution to journalArticle

Ohashi, Toshio ; Yorozu, Atsunori ; Toya, Kazuhito ; Saito, Shiro ; Momma, Tetsuo. / Serial changes of international prostate symptom score following I-125 prostate brachytherapy. In: International Journal of Clinical Oncology. 2006 ; Vol. 11, No. 4. pp. 320-325.
@article{df226f7b7d2e483c96485985adb48194,
title = "Serial changes of international prostate symptom score following I-125 prostate brachytherapy",
abstract = "Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8{\%}) and it returned to within 3 points of the baseline in 64 (62.1{\%}) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.",
keywords = "Brachytherapy, Iodine-125, IPSS, Prostate cancer, Urinary morbidity",
author = "Toshio Ohashi and Atsunori Yorozu and Kazuhito Toya and Shiro Saito and Tetsuo Momma",
year = "2006",
month = "8",
doi = "10.1007/s10147-006-0584-3",
language = "English",
volume = "11",
pages = "320--325",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Serial changes of international prostate symptom score following I-125 prostate brachytherapy

AU - Ohashi, Toshio

AU - Yorozu, Atsunori

AU - Toya, Kazuhito

AU - Saito, Shiro

AU - Momma, Tetsuo

PY - 2006/8

Y1 - 2006/8

N2 - Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8%) and it returned to within 3 points of the baseline in 64 (62.1%) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.

AB - Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8%) and it returned to within 3 points of the baseline in 64 (62.1%) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.

KW - Brachytherapy

KW - Iodine-125

KW - IPSS

KW - Prostate cancer

KW - Urinary morbidity

UR - http://www.scopus.com/inward/record.url?scp=33748094619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748094619&partnerID=8YFLogxK

U2 - 10.1007/s10147-006-0584-3

DO - 10.1007/s10147-006-0584-3

M3 - Article

VL - 11

SP - 320

EP - 325

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -